TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11176083

Group type: EXPERIMENTAL
Intervention: Remifentanil (loading dose 1 microg/kg; maintenance infusion, 0.25 microg x kg(‐1) x min‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alfentanil (loading dose, 50 microg/kg; maintenance infusion, 1 microg x kg(‐1) x min‐1)
Number of subjects: 40
Study: 9595857

Group type: EXPERIMENTAL
Intervention: TCR gamma/delta gene rearrangement in peripheral blood lymphocytes and cerebral white matter of MS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of V delta‐J delta rearrangement patterns
Number of subjects: 0
Study: 7996800

Group type: EXPERIMENTAL
Intervention: High NaCl intake (240 mmol NaCl per day for two weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low NaCl intake (40 mmol NaCl per day for 2 weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Active kallikrein excretion
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Plasma atrial natriuretic peptide levels
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Correlation between urinary kallikrein and plasma atrial natriuretic peptide
Number of subjects: 37
Study: 3173600

Group type: EXPERIMENTAL
Intervention: imidazole-2-hydroxibenzoate
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 28306685

Group type: EXPERIMENTAL
Intervention: Aquatic Treadmill Exercise (ATE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Land-Based Exercise (LBE)
Number of subjects: 20
Study: 27237769

Group type: EXPERIMENTAL
Intervention: IM IFN beta‐1a 30 mcg once weekly (full-dose group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IM IFN beta‐1a 15 mcg once weekly for 2 weeks then 30 mcg once weekly (titration group)
Number of subjects: 100
Study: 24508036

Group type: EXPERIMENTAL
Intervention: 100μg gE/AS01B (one dose)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: 25μg gE/AS01B (two doses, two months apart)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: 50μg gE/AS01B (two doses, two months apart)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: 100μg gE/AS01B (two doses, two months apart)
Number of subjects: 714

Group type: COMPARATOR
Intervention: 100μg gE/saline (two doses, two months apart)
Number of subjects: 714
Study: 22730850

Group type: EXPERIMENTAL
Intervention: Higher protein milk supplement
Number of subjects: 35

Group type: COMPARATOR
Intervention: Higher carbohydrate supplement
Number of subjects: 35
Study: 20414783

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A 2% drops
Number of subjects: 78

Group type: COMPARATOR
Intervention: Polyvinyl alcohol 1.4% drops (Control)
Number of subjects: 78
Study: 18498912

Group type: EXPERIMENTAL
Intervention: Test formulation of aceclofenac 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of aceclofenac 100 mg
Number of subjects: 24
Study: 15342210

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1.5 mg/kg subcutaneous (s.c.) once daily
Number of subjects: 201

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) intravenous (i.v.) adjusted to aPTT 1.5‐2.5 times control
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 201

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 201
Study: 11249891

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg, uptitrated to 32 mg after 4 weeks
Number of subjects: 251

Group type: COMPARATOR
Intervention: Amlodipine 5 mg, uptitrated to 10 mg after 4 weeks
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 251

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 251
Study: 9972901

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (4-min aortic cross-clamping and 6-min reperfusion)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (only ischaemic insult of operating procedure)
Number of subjects: 56
Study: 8049846

Group type: EXPERIMENTAL
Intervention: Amiloride (0.3 mg/m2 body surface area)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 12
Study: 3352886

Group type: EXPERIMENTAL
Intervention: Group A (steroids preoperatively and for 4 days postoperatively)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Group B (steroids pre- and postoperatively for 1 day)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Group C (no steroids)
Number of subjects: 222
Study: 30077820

Group type: EXPERIMENTAL
Intervention: Positive results in pediatric ophthalmology studies
Number of subjects: 174

Group type: COMPARATOR
Intervention: Negative results in pediatric ophthalmology studies
Number of subjects: 174
Study: 28068207

Group type: COMPARATOR
Intervention: 5.25% sodium hypochlorite
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite activated by diode laser
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Saline solution activated by diode laser
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Saline solution with methylene blue dye activated by diode laser
Number of subjects: 128

Group type: COMPARATOR
Intervention: Saline solution (positive control)
Number of subjects: 128
Study: 25724847

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (3 mg, six 2-monthly oral doses over 1 year)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 23464674

Group type: EXPERIMENTAL
Intervention: Four-month treadmill and overground walking program (30 min, thrice per week)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Two-month treadmill and overground walking program (30 min, thrice per week)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102
Study: 20609398

Group type: EXPERIMENTAL
Intervention: DTaP(5)‐IPV/Hib administered concurrently with PCV7
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTaP(5)‐IPV/Hib administered at separate visits (staggered group)
Number of subjects: 0
Study: 18028587

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 135

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 135
Study: 16984993

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone therapy (Intrinsa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral methyltestosterone
Number of subjects: 0
Study: 12622671

Group type: EXPERIMENTAL
Intervention: Use of color-coded materials and Broselow Pediatric Emergency Tape in simulated resuscitations
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control scenarios without color coding
Number of subjects: 28
Study: 10671676

Group type: EXPERIMENTAL
Intervention: CAV/PE‐W (dose‐intensive weekly alternating chemotherapy)
Number of subjects: 76

Group type: COMPARATOR
Intervention: CAV/PE (standard alternating chemotherapy)
Number of subjects: 76
Study: 9137950

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 8148854

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 200 mg sustained-release
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ketoprofen 200 mg sustained-release
Number of subjects: 116
Study: 3484547

Group type: EXPERIMENTAL
Intervention: Phenobarbital or primidone withdrawal
Number of subjects: 8

Group type: COMPARATOR
Intervention: No drug change (control)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Addition or deletion of a single drug other than barbiturate
Number of subjects: 8
Study: 29726280

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. infantis R0033
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus R0052
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum R0071
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27546373

Group type: EXPERIMENTAL
Intervention: Raloxifene 60mg/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 24447885

Group type: EXPERIMENTAL
Intervention: Substance abuse treatment
Number of subjects: 176
Study: 22689417

Group type: EXPERIMENTAL
Intervention: Ranolazine (750/1000 mg bid)
Number of subjects: 258
Study: 20938175

Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride (400 mg loading dose on day 1, followed by 200 mg daily)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Levofloxacin (200 mg orally twice daily for 7-14 days)
Number of subjects: 284
Study: 18549888

Group type: EXPERIMENTAL
Intervention: VBLOC therapy (intra-abdominal vagal blocking)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: VBLOC therapy
Number of subjects: 31
Study: 15321783

Group type: EXPERIMENTAL
Intervention: Risk reduction intervention
Number of subjects: 146

Group type: COMPARATOR
Intervention: Community educational standard of care
Number of subjects: 146
Study: 11177300

Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 0
Study: 9076203

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg tablet)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8360066

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 13

Group type: COMPARATOR
Intervention: No epidural analgesia
Number of subjects: 13
Study: 3759781

Group type: EXPERIMENTAL
Intervention: 0.35 ppm O3 exposure for 1 hour over 4 consecutive days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Filtered air (FA) exposure
Number of subjects: 8
Study: 28253307

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 126
Study: 25663309

Group type: EXPERIMENTAL
Intervention: Low-intensity antenatal intervention (2-h psycho-educational programme)
Number of subjects: 83
Study: 24384495

Group type: EXPERIMENTAL
Intervention: Intravaginal 5% 5‐fluorouracil (5‐FU) applied once every 2 weeks for a total of 16 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Observation (control group).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravaginal 5% 5‐fluorouracil (5‐FU) combined with cervical biopsy, Papanicolaou smear, and HPV results.
Number of subjects: 60
Study: 22639944

Group type: EXPERIMENTAL
Intervention: Yoga intervention (eight weeks of weekly teacher-led yoga class and home-based daily yoga practice delivered by DVD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Current best practice care (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 40
Study: 19573210

Group type: EXPERIMENTAL
Intervention: Interactive multimedia patient education for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine patient education for 3 months
Number of subjects: 60
Study: 17295995

Group type: EXPERIMENTAL
Intervention: Treatment with incentives I
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Treatment with incentives II
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 66
Study: 15626318

Group type: EXPERIMENTAL
Intervention: Bio‐Oss + Bio‐Gide membrane (test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bio‐Gide membrane (control)
Number of subjects: 20
Study: 10874062

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 9349928

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8195850

Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 60
Study: 2879344

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HO) with diazepam (5 mg) in group I
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HO) in group II
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (group III)
Number of subjects: 49
Study: 30982983

Group type: EXPERIMENTAL
Intervention: Vitamin E pretreatment for 24 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PIAS1-shRNA infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: High glucose and PA exposure
Number of subjects: 0
Study: 29349539

Group type: EXPERIMENTAL
Intervention: Experimental bundle with intraperitoneal lavage with antibiotic solution, fascial closure with Triclosan-coated sutures, and Mupirocin ointment application on skin staples
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard bundle (Group 1)
Number of subjects: 198
Study: 26936859

Group type: EXPERIMENTAL
Intervention: Iron supplementation in infancy
Number of subjects: 1482

Group type: COMPARATOR
Intervention: Placebo in pregnancy/Placebo in infancy
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Placebo in pregnancy/Iron in infancy
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Iron in pregnancy/Placebo in infancy
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Iron in pregnancy/Iron in infancy
Number of subjects: 1482
Study: 25281223

Group type: EXPERIMENTAL
Intervention: MDMA (0.5 or 1.0 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23812296

Group type: EXPERIMENTAL
Intervention: UPA silencing in control cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UPA silencing in lipid-loaded VSMC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UPA acting as UPAR ligand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cells (not lipid-loaded)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: agLDL exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 0
Study: 20876598

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 174

Group type: COMPARATOR
Intervention: Systemic heparin anticoagulation
Number of subjects: 174
Study: 17959585

Group type: EXPERIMENTAL
Intervention: i.v. acetaminophen
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 150
Study: 16514325

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 0
Study: 14588132

Group type: EXPERIMENTAL
Intervention: Lottery/Postcard
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Money/Postcard
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Postcard only
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Lottery only
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Money only
Number of subjects: 3000

Group type: COMPARATOR
Intervention: No incentive/No postcard
Number of subjects: 3000
Study: 11094668

Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg administered at 1 minute prior to propofol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg administered at 2 minutes prior to propofol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg administered at 4 minutes prior to propofol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg administered at 6 minutes prior to propofol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg administered at 10 minutes prior to propofol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam (any timing)
Number of subjects: 120
Study: 8779456

Group type: EXPERIMENTAL
Intervention: Glove and gown use
Number of subjects: 181

Group type: COMPARATOR
Intervention: Glove use only
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Environmental cultures
Number of subjects: 181
Study: 1416164

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 20
Study: 31865288

Group type: EXPERIMENTAL
Intervention: Chakrayoga Meditation Program (twice a week for 2 hours during 6 weeks, consisting of 1 hour of Chakrayoga and 1 hour of meditation)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97
Study: 29079365

Group type: EXPERIMENTAL
Intervention: Continuous-flow cryocompression therapy (CFCT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 125
Study: 25875777

Group type: EXPERIMENTAL
Intervention: Deferoxamine mesylate (62 mg/kg/day, maximum dose not to exceed 6000 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no deferoxamine mesylate)
Number of subjects: 42
Study: 25087476

Group type: EXPERIMENTAL
Intervention: Low-dose DENVax vaccine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-dose DENVax vaccine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (low-dose)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (high-dose)
Number of subjects: 96
Study: 22212113

Group type: EXPERIMENTAL
Intervention: UMI irrigated with essential oils (EOs)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: UMI irrigated with 0.2% chlorhexidine (CHX)
Number of subjects: 45

Group type: COMPARATOR
Intervention: UMI irrigated with distilled water (Control)
Number of subjects: 45
Study: 18775625

Group type: EXPERIMENTAL
Intervention: e‐Getgoing (Internet-based group counseling)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Onsite group counseling (routine)
Number of subjects: 37
Study: 18633464

Group type: EXPERIMENTAL
Intervention: Frequent Therapy (FT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Minimal Therapy (MT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both MT and FT
Number of subjects: 42
Study: 16198877

Group type: EXPERIMENTAL
Intervention: Mitral valve repair with surgical correction of annular disjunction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitral valve repair without surgical correction of annular disjunction
Number of subjects: 0
Study: 12135015

Group type: EXPERIMENTAL
Intervention: L‐NMMA (12 mg/kg within 5 min, followed by a maintenance infusion of 6.7 mg/kg/h i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10192014

Group type: EXPERIMENTAL
Intervention: Shuck test
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intraoperative measurement using a Steinman pin and an adjustable caliper
Number of subjects: 64
Study: 8523851

Group type: EXPERIMENTAL
Intervention: Drug-resistant pulmonary tuberculosis patients continuing chemotherapy
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Previously untreated pulmonary tuberculosis patients
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Patients with drug-resistant tuberculosis
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Patients with drug-resistant pulmonary tuberculosis
Number of subjects: 266
Study: 2407098

Group type: EXPERIMENTAL
Intervention: Dietary intervention with counseling to achieve changes in calorie, sodium, and/or potassium intake.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated assessments of diet based on participant recording.
Number of subjects: 0
Study: 6779371

Group type: EXPERIMENTAL
Intervention: Metronidazole (600‐1200 mg daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin (1.6 g daily)
Number of subjects: 21
Study: 30003988

Group type: EXPERIMENTAL
Intervention: Glycopyrronium tosylate (GT) 3.75% applied once daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle applied once daily for 4 weeks
Number of subjects: 0
Study: 27297740

Group type: EXPERIMENTAL
Intervention: Intervention group (n=155)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (n=146)
Number of subjects: 301
Study: 25881461

Group type: EXPERIMENTAL
Intervention: Xingnaojing Injection (20 mL per day for 14 days), followed by Chinese medical granules for 21 days, and Naoxueshu Oral Liquid (10 mL, 3 times per day till 3 months)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Basic treatment of Western internal medicine
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 228
Study: 23740822

Group type: EXPERIMENTAL
Intervention: Online audit and feedback (group A)
Number of subjects: 258

Group type: COMPARATOR
Intervention: No feedback (group B)
Number of subjects: 258
Study: 20826553

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 811
Study: 19729890

Group type: EXPERIMENTAL
Intervention: Calcium plus oral cholecalciferol (150,000 IU once a month for the first 2 months, followed by 90,000 IU once a month for the last 4 months)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Calcium plus monthly placebo
Number of subjects: 56
Study: 18031640

Group type: EXPERIMENTAL
Intervention: Composite teaching (model/video teaching)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cadaver-based teaching
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both teaching methods
Number of subjects: 10
Study: 14717748

Group type: EXPERIMENTAL
Intervention: D(LO2)2C (estimated pulmonary diffusing capacity for O2 during exercise)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Refined analytical procedure for estimating D(LO2)
Number of subjects: 11
Study: 11718495

Group type: COMPARATOR
Intervention: Cycloserine 500 mg after a 12-hour fast (reference)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cycloserine 500 mg with a high-fat meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cycloserine 500 mg with orange juice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cycloserine 500 mg with antacids
Number of subjects: 12
Study: 9429006

Group type: EXPERIMENTAL
Intervention: Deceptive advertising message
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neutral advertising message
Number of subjects: 15

Group type: COMPARATOR
Intervention: Warning advertising message
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bare platform
Number of subjects: 15
Study: 8239101

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg/10 mL) administered at 10 mL/min for ten minutes, with up to 3 mg of open-label flumazenil if no response.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo (10 mL/min) administered for ten minutes.
Number of subjects: 170